Theratechnologies Inc T.TH

So anything good coming out soon

[Biobob]

Th management behaving like NATO in Ukraine... doing nothing... but how could they, the market is not good now, they have no news yet from Anderson, they can't tell us anything before AGM so that we don't send them in retirement, so that theu can execute their final solution.. OO no.2 in the confort of reelection.

[Biobob]

Sorry not doing nothing.. all collecting very generous salaries year after year... a cool 2M for Paul... 

[SPCEO1]

I have had my complaints about management but doing nothing is not one of those complaints. As JFM repeatedly reminds us, you have to wait for a trial to be over to make claims the market will pay attention to. But if you are short the stock, as would appear to be the case given the tenor of your posts, you had better be careful because the overdue trial results cannot be postponed much longer

[canadapiet]

If results show some positive effect, wouldn't there be more "signs" ??? Sick patients should show "positive progress" and many on the trial would know that! The lacklustre behavior of the Management and the depressed share price says it all!  So, mediocre results at best, share price stays = or down, and another long waiting period!! So evidently, another O O at a

[Biobob]

It does look like pre Trogarzo approval in 2018....going down on low volume.. risk aversion combined to market hate for the company does'nt look like leaks are making it trought yet all bets are on still.

[qwerty22]

Bicycle landed strong Ph1 data that caught the market by surprise. Even though they had more eyes on them because of all the good things like collaborations that they'd achieved prior to that. It's interesting to look at bicycles news flow to understand the constraints on a company. They initially reported a couple of PRs. One of those PRs turned into a CR on the next scan after that

[SPCEO1]

BCYC is down about 25% YTD so it does not appear the market reacted welll to this data. It does have a boatload of analysts follwoing it including GS and MS, has $437 million in cash and is only burning about as much as TH - around $14 million last year. Revenues are less than $12 million. Market cap is $1.3 billion.  From a science perspective, what is it that gives BCYC such a better

[jfm1330]

They have three PDCs in human clinical trials, one in phase II, and they have efficacy data in many patients. Just that is more than enough to have much higher valuation. Their chemistry is also more advanced, and they use better cytotoxic agents than docetaxel, agents to which resistance is less likely. They are where Thera hope to be in a few years with more than one PDC. The only thing that in

[SPCEO1]

It would not surprise me if TH-1902 is in at least one phase II trial before the end of this year. It could be more than that if they see signs of efficacy in more than one cancer type and it sounded like a basket trial might be a possibility in phase II as well but they did not sound convinced about that. If all goes well, TH has indicated they might have an approved cancer drug by 2025. I am not

[qwerty22]

I remember once ha=ing a conversation with the ceo of a preclinical biotech I worked at. It revolved around whether we would be principally a platform offering or a product offering company. The importance being that the type of work we did and how we positioned ourselves would be different depending on which path we took. You can think of product and platform as two Poles and there being a

[SPCEO1]

We should probably keep our expectations low on the phase 1a results reaction, even though I expect it to be interesting, because there is no significant institutional or retail interest in TH's stock right now. Now, I would note that Cantor covers BCYC and has a $100 price target on it and the average price target is $71. So, since TH has Cantor as a potential new firm to cover it following

[jfm1330]

In french we say: "avec des si on mettrait Paris en bouteille." Which can be translated by something like: "with If you could put Paris in a bottle". So yes, if results are good and so on, a lot of doors would open. But for now all that need confirmation. 

[Bucknelly21]

By no means do i mean any disrespect, but jfm has the same sort of thought process as Philippe. Like results produce before excitement except thats just not true. You would never see ipos for companies like uber, and rivian ect getting valued in the multi billions if their arguments had any validity. Clearly you are a wise person jfm but it seems to be a Canadian train of thought to handle the ir

[Trogarzon]

Well said.. I second that.  Beyond bad management.. just awfull.  Unless they pull this th1902 rabit I'm bailing.  I won't stay for another 3$ deal to finance the 50m Nash 2/3 stuff... probably going to waste.. just like the 50m they raised last time.. do you see 50m worth of deals or value creation.  I don't think so.

[Bucknelly21]

I mean if they hit with cancer then im fine but before this it was nash, i waited, then before that trogarzo, i waited, i blame myself but as a shareholder who stuck with them theough it all i would be nice for an assist from the company 

[palinc2000]

You reap what you sow!!!   There has never been a consistent strategic plan over the company 's history.Tesamorelin was  and still is a great product  imo but for some reason the company did not in the past pursue any development with tesamorelin and only got involved after the Grinspoon study results were released ...and even then maybe the right  decision  then

[PWIB123]

And another reason why I still intend to vote against every single one of them.  

[SPCEO1]

Some practical points that I think are worth considering on this topic: 1.) One week from right now, we may be feeling a lot better about management. Now it will likely take a little longer than that to find out about the results of the phase 1a trial but we can already be pretty confidentthat something good has happened there that gives us reason to believe TH-1902's longer term prospects

[Biobob]

Can we mandate Wino to lobby our interest to the C suite.... I meen hiring a cheif of staff and still no IR replacement.. Jesus.. how dumb can you be.

[SPCEO1]

Hiring a really good IR person is likely going to be a challenge until they have something to sell to investors. If you were a talented IR person, you would have many job options before you. Why would you jump onto the nearly empty bandwagon at TH before they reported out something of interest on cancer? If they are going to get someone good, they are likely going to have to pay alot to compensate

[Biobob]

They never heard of Outsourcing... Molson guy heads a communication empire... go figure why they still have an accountant running IR...

[SPCEO1]

TH's CFO has a background in investment banking. He is more a strategy guy than a CPA type. He is capable of doing a decent job with IR but it really has not worked out well in recent years. I will give an example of something that happened that may explain that. Three sizable investors, including me, who collectively own 14% of the stock, told him and the CEO that the low price of the stock

[Biobob]

I'm far from convinced that if they reverse split the stock that large institutions will come... it's like the saying.. Built it and they will come... in Montreal they are building a public transport network with no user demand... billions wasted and garanteed annual gigantic deficits for the taxtapers.. another election promise on the back of taxpayers... just an example.

[SPCEO1]

have a positive impact on the market cap eventually. Ultimately, the biggest mover for the stock will be good data and wise financing decisions that put TH in the sight of investors who currently are not paying any attention to it at all. But there is no reason not to try and optimize the situation by doing a reverse stock split tied to good cancer news.

[qwerty22]

Everything can only start with good cancer data, that's the bottom line for now.

[SPCEO1]

Obviously, a part of the first paragraph in my post below  got cut off somehow. Don't have time at the moment to recreate it - sorry.

[palinc2000]

Dont you think that good cancer news will /would propel the depressed SP to a level that  would remove whatever regulatory concerns you may have..... 

[SPCEO1]

Maybe, but I would say it is not the most likely scenario. This is, after all, just a phase 1a test result and the number of patients that had a qualifying tumor is going to be pretty small. The stock price would need to surpass $5 to start breathing easier on that front so we would need it to double or more and maintain that price. With an offering likely coming up at some point soon and the help

[Wino115]

Our views were heard last year and they acceded about half what we wanted -got a financial type with some Canadian and US market experience, but part of the Canadian business club. I would hope the current Board would not allow extraneous fixed cost employees to enter the company unless and until the prospects for oncology are much clearer around the potential future financial rewards.  The

[PWIB123]

Totally agree that we should all formulate questions.  Bombard them, so they know they are leaving gaps wide open for speculation and doubt and have an active gropu of investors who care.  This is a way I can act like an owner.  I'll spend some time formulating questions from my perspective, but honestly, I'm relying on yours and others expertise here when it comes to

[PWIB123]

I fully understand these things, and it's because I don't believe my vote or anyone elses will truly have an impact that I can throw logic and common sense out the window and vote purely on emotion.  I wouldn't mind sending an aggressive message.  Every one should vote their conscious and mine leads to voting against every one of them.  Here's how firm I am on this

[Wino115]

Regardless of numbers, everyone should vote how they believe it should be counted, even if majorities aren't hit.  Many did this last year and I think it does send a message to the Chairwomen and CEO on what shareholders view as the importance of the skills as we see it that the individual Board member may bring.  Shareholders could be completely wrong since we don't read Board

[jfm1330]

Funny to see how things can change, former CEO was lambasted here when he was in charge and he is the guy who decided to buy Katana, which everybody is hoping will give a new life to this company and board members at that time were also denigrated. When Levesque came as the new CEO many were excited. Oh a guy from a big pharma! He will turn things around. Since then, many new board members were

[FredTheVoice]

Yep, and PALINC is one of those who likes to criticize you, and who was hoping big time that Levesque would be fantastic....... JFM, you just dont play his game and thats worth mentionning. FTV.

[palinc2000]

Freddy I really enjoy your in depth analysis and your business acumen....   

[FredTheVoice]

Yep, your right on that one, with THERA I made a huge mistake when we look at my choices in the last years in that bull market. I admit. Hope for the best. And, on the other side, I never will be waiting for you to say your sorry or wrong with your human acumen...... GLTA, FTV.

[ANALIAS00]

Hi Fred, I think Palinc's input is always very realistic in all time and I appreciate his input a lot. I think he could be less in JFM's back and reply to his input with less emotions and sarcastics comment but we saw worse comment from others. I also like JFM but he is very wrong on one thing. He wont admit that in between news, there is a lot a companie can and should do for shareholders

[jfm1330]

Levesque pushed the NASH narrative very hard and needed to subtly backpedal about it. I went from Thera will go alone in a large phase III, to a partner search, and now scaling back to a phase IIb/III. He also pushed a lot the SORT1+ program. Remember the KOL presentation, he was very positive and talked of a new way to treat cancer and so on and they were very optimistic about timelines, when in

[Biobob]

Next monday is AACR Th1902 Posters... hope we learn more than what's in the papers on TH1902 precilical successes... lots of cured mices... 

[SPCEO1]

No one should expect for some new piece of info to come out on the three posters. What we can hope for is that people in the industry start a buzz about PDC's and Sort1+ that eventually makes its way to the stock price. But I don't think it is likely to have a new revelation that was not in the posters to come out in such meetings. I am hoping we get some more info about the importance of

[SPCEO1]

See my coments in red in the body of your post below:

[jfm1330]

We will never agree on the stock promotion and investors relations. I just showed that Levesque was quite aggressive in his public statements on all fronts, and up to now he has nothing to show for it. Maybe it will change, but for now he did nothing special, nothing that Tanguay would not have made just as good, or bad, I guess it depends on the point of view. Also, the last financing was

[PWIB123]

jfm1330 - The problem is they didn't continue to communicate when their plans didn't work out.  They hid under a rock and left everything open to speculation and interpration.  That's a negative compounding effect and a communications 101 no-no.  SPCE01 has shared many things they could've done in terms of communication, and you are choosing to ignore those

[FredTheVoice]

ANALIA WROTE: "Hi Fred, I think Palinc's input is always very realistic in all time and I appreciate his input a lot. I think he could be less in JFM's back and reply to his input with less emotions and sarcastics comment but we saw worse comment from others. I also like JFM but he is very wrong on one thing. He wont admit that in between news, there is a lot a companie can and should

[qwerty22]

2021 was their break out year. When this data unfolded.  It's down from that.